Last reviewed · How we verify

NCT05523531: QUALVIDON2

Prospective Single-center Long-term Follow-up Study of a Series of Cases Previously Included in the QUALVIDON Study

Completed Last updated 8 December 2022
What this trial tests

trial testing Self-administered questionnaires in Dry Eye in 14 participants. Completed in 6 December 2022.

Timeline
15 September 2022
Primary endpoint
6 December 2022
6 December 2022

Quick facts

Lead sponsorFondation Ophtalmologique Adolphe de Rothschild
StatusCompleted
Study typeOBSERVATIONAL
Enrollment14
Start date15 September 2022
Primary completion6 December 2022
Estimated completion6 December 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Dry Eye or Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dry eye affects millions of people around the world. Some dry eye patients complain of neuropathic eye pain that can affect their quality of life. From August 2016 to June 2017, the QUALVIDON study (NCT03296111), conducted at the Adolphe de Rothschild Foundation Hospital, assessed pain and its impact on quality of life using self-administered questionnaires in a series of dry eye patients. This 2nd study, entitled QUALVIDON2, focuses on the outcome of patients previously included in QUALVIDON.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Self-administered questionnaires

Trials testing the same drug.

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05523531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing